Rallybio (NASDAQ:RLYB – Get Free Report) and Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings and price targets for Rallybio and Rapport Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rallybio | 1 | 0 | 0 | 0 | 1.00 |
| Rapport Therapeutics | 1 | 0 | 8 | 1 | 2.90 |
Rapport Therapeutics has a consensus target price of $58.83, suggesting a potential upside of 57.56%. Given Rapport Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Rallybio.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rallybio | $858,000.00 | 98.61 | -$8.98 million | ($4.34) | -3.68 |
| Rapport Therapeutics | N/A | N/A | -$111.48 million | ($2.60) | -14.36 |
Rallybio has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Rallybio and Rapport Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rallybio | -911.07% | -55.79% | -51.48% |
| Rapport Therapeutics | N/A | -24.78% | -23.44% |
Risk and Volatility
Rallybio has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
Institutional and Insider Ownership
90.3% of Rallybio shares are owned by institutional investors. 10.3% of Rallybio shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Rapport Therapeutics beats Rallybio on 10 of the 14 factors compared between the two stocks.
About Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
About Rapport Therapeutics
Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
